Unicycive Therapeutics In... (UNCY)

AI Score

Unlock

0.54

-0.02 (-4.34%)

At close: Feb 28, 2025, 3:59 PM

0.55

2.67%

After-hours: Feb 28, 2025, 04:00 PM EST

Company Description

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States.

It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury.

The company was incorporated in 2016 and is based in Los Altos, California.

Unicycive Therapeutics Inc.

Country	United States
IPO Date	Jul 12, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	14
CEO	Dr. Shalabh K. Gupta M.D., MPA

Contact Details

Address: 4300 El Camino Real Los Altos, California United States
Website	https://www.unicycive.com

Stock Details

Ticker Symbol	UNCY
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001766140
CUSIP Number	90466Y103
ISIN Number	US90466Y1038
Employer ID	81-3638692
SIC Code	2834

Key Executives

Name	Position
Dr. Shalabh K. Gupta M.D., MPA	Founder, Chairman, Chief Executive Officer & President
John W. Townsend CPA	Chief Financial Officer
Douglas Jermasek M.B.A.	Executive Vice President of Corporate Strategy
Dr. Pramod Gupta Ph.D.	Executive Vice President of Pharmaceutical & Business Operations

Latest SEC Filings

Date	Type	Title
Feb 19, 2025	4	Filing
Feb 14, 2025	SCHEDULE 13G/A	[Amend] Filing
Feb 14, 2025	SCHEDULE 13G/A	[Amend] Filing
Feb 06, 2025	SCHEDULE 13G/A	[Amend] Filing
Jan 07, 2025	8-K	Current Report
Dec 20, 2024	SCHEDULE 13G/A	[Amend] Filing
Dec 20, 2024	SCHEDULE 13G/A	[Amend] Filing
Nov 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial own...
Nov 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial own...
Nov 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial own...

View All SEC Filings